Spark Therapeutics Inc (NASDAQ:ONCE) – Analysts at SunTrust Banks issued their FY2022 EPS estimates for Spark Therapeutics in a research report issued on Wednesday. SunTrust Banks analyst E. Nash forecasts that the biotechnology company will earn $7.91 per share for the year. SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock.

A number of other research firms have also issued reports on ONCE. Goldman Sachs Group reaffirmed a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a research note on Friday, October 6th. BMO Capital Markets set a $89.00 target price on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 10th. Cowen reaffirmed a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Barclays upped their target price on Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Finally, Cantor Fitzgerald reduced their target price on Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating on the stock in a research note on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. Spark Therapeutics presently has an average rating of “Buy” and an average target price of $76.03.

Spark Therapeutics (ONCE) traded down $1.28 during mid-day trading on Friday, reaching $50.56. The company had a trading volume of 1,343,479 shares, compared to its average volume of 1,470,000. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75. The stock has a market cap of $1,870.00 and a price-to-earnings ratio of -7.02.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. During the same period in the previous year, the company posted ($1.07) EPS. Spark Therapeutics’s quarterly revenue was up 45.8% compared to the same quarter last year.

Several hedge funds have recently added to or reduced their stakes in ONCE. Ameritas Investment Partners Inc. increased its holdings in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Spark Therapeutics during the 2nd quarter worth $143,000. BNP Paribas Arbitrage SA increased its holdings in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. increased its holdings in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Spark Therapeutics during the 3rd quarter worth $225,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

In other news, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.54, for a total value of $1,430,800.00. Following the sale, the chief executive officer now owns 250,000 shares of the company’s stock, valued at $17,885,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,309 shares of company stock valued at $4,621,085. Insiders own 7.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics Inc (ONCE) Forecasted to Post FY2022 Earnings of $7.91 Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/05/spark-therapeutics-inc-once-forecasted-to-post-fy2022-earnings-of-7-91-per-share.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.